Diabetic retinopathy (DR) is the progressive degeneration of retinal blood vessels and neurons. Inflammation is known to play an important role in the pathogenesis of DR. During diabetes, metabolic disorder leads to the release of damage-associated molecular patterns (DAMPs) both in the retina and elsewhere in the body. The innate immune system provides the first line of defense against the DAMPs. In the early stages of DR when the blood retinal barrier (BRB) is intact, retinal microglia and the complement system are activated at low levels. This low-level of inflammation (parainflammation) is believed to be essential to maintain homeostasis and restore functionality. However, prolonged stimulation by DAMPs in the diabetic eye leads to maladaptation of the innate immune system and dysregulated para-inflammation may contribute to DR development. In the advanced stages of DR where immune privilege is comprised, circulating immune cells and serum proteins may infiltrate the retina and participate in retinal chronic inflammation and retinal vascular and neuronal damage. This review discusses how the innate immune system is activated in diabetes and DR. The view also discusses why the protective immune response becomes detrimental in DR.
Introduction
The immune system consists of innate and adaptive immunity. Innate immunity provides an early, non-specific, first line of defense against almost any substance that threatens the host, whereas adaptive immunity offers pathogen or antigen specific protection. The immune system protects the host from both exogenous pathogens, such as the pathogen-associated molecular patterns (PAMPs) (Newton & Dixit, 2012; Mogensen, 2009 ) and endogenous danger molecules (known as damage-associated molecular patterns, DAMPs) (Miller et al., 2011) including oxidized or glycated proteins, mis-located proteins/antigens, and intracellular contents (e.g., uric acid, DNA, RNA, etc.) released by necrotic cells. Innate immune cells express various receptors (pattern recognition receptors, PRRs) for recognizing PAMPs and DAMPs (Tang, Kang, Coyne, Zeh, & Lotze, 2012) , which induce both rapid defense and more delayed cellular responses. The common PRRs responsible for PAMP/DAMP detection include toll-like receptors (TLRs) Rock, Hardiman, Timans, Kastelein, & Bazan, 1998 , C-type lectin receptors (CLR) Richardson & Williams, 2014 , receptor for advanced glycation end-products (RAGE) Ramasamy et al., 2005, NOD-like receptors (NLRs), and RIG-like receptors (RLRs) Carneiro, Magalhaes, Tattoli, Philpott, & Travassos, 2008. During diabetes, insulin-dependent cells may suffer malnutrition; whereas insulin-independent cells may be stressed from the sustained hyperglycemic environment. Metabolic disorder can generate both intracellular (e.g., accumulation of unfolded/misfolded proteins) and extracellular (e.g., advanced glycation end-products, AGE) DAMPs. The intracellular DAMPs may be sensed by the PRRs in the cytosol and induce cell autonomous inflammatory response (Chen & Xu, 2015) , whereas the extracellular DAMPs are often detected by cell surface PRRs and induce inflammatory response at tissue level or even systemic inflammation. The physiological role of the immune response is to remove the DAMPs and maintain homeostasis. Compelling evidence suggests that chronic inflammation in diabetes contributes to the pathogenesis of various complications, including diabetic retinopathy (DR). This review discusses how the hyperglycemic condition affects the innate immune system and explores why the protective innate immune response becomes detrimental in diabetic complications such as DR.
The effect of diabetes on the innate immune system

Dysregulated innate immune cell activation in diabetes
The innate immune cells consist of polymorphonuclear leukocytes (i.e., neutrophils, basophils, mast cells and eosinophils), (Casqueiro, Casqueiro, & Alves, 2012) . This may be attributed to the hyperglycemic environment mediated enhancement of virulence of some pathogens. The dysfunction of the innate immune system, including innate immune cells and the complement system may also contribute to increased infection. Phagocytosis and bactericidal activity of polymorphonuclear cells are reduced in diabetes patients (Cutler, Eke, Arnold, & Van Dyke, 1991; Krause, Brachmann, Losche, Hoffmann, & Gangler, 1992; Lecube, Pachon, Petriz, Hernandez, & Simo, 2011) . Neutrophils from diabetes patients have reduced ability to migrate towards pathogens and chemokines (Cutler et al., 1991; Krause et al., 1992) .
Despite reduced phagocytosis and bactericidal activity, neutrophils and monocytes from diabetic patient are more active than those from healthy control. For example, increased adhesion molecule expression (Bouma, Lam-Tse, Wierenga-Wolf, Drexhage, & Versnel, 2004; Devaraj, Jialal, Yun, & Bremer, 2011) and proinflammatory cytokine production (Bradshaw et al., 2009; Hatanaka, Monteagudo, Marrocos, & Campa, 2006) has been observed in monocytes and neutrophils from type 1 and type 2 diabetes (T1D and T2D) patients (Hatanaka et al., 2006; Josefsen, Nielsen, Lorentzen, Damsbo, & Buschard, 1994; Wierusz-Wysocka et al., 1987) . The increased innate immune cell activation is often associated with diabetic complications. We have shown that circulating CD11b monocytes from diabetic mice are more active and express higher levels of chemokine receptor CCR5 (Serra et al., 2012) . They are preferentially trapped in retinal microvasculature and may contribute to diabetic retinal vasculopathy (Serra et al., 2012 patients with microvascular or macrovascular complications compared with patients without complications (Min et al., 2012) . In addition, increased PRR, such as TLR2 and TLR4 expression has been observed in monocytes from T2D patients (Dasu, Devaraj, Zhao, Hwang, & Jialal, 2008) , and is known to be involved in various diabetes-induced complications (Devaraj et al., 2011; Szasz, Wenceslau, Burgess, Nunes, & Webb, 2016) , including DR (Wang et al., 2014 ) (see below). Higher levels of TLR2/TLR4 were also reported in the NOD mice (a model of T1D) and the expression is positively correlated with the transcription factor, nuclear factor kappa B (NF-jB) expression and inflammation (Mohammad et al., 2006) . In addition, activation of the NLRs, in particular NLRP3 is known to be involved in obesity and T2D (Wada & Makino, 2016) . The decreased phagocytosis and bactericidal activity and increased TLR expression and proinflammatory cytokine production by monocytes and neutrophils are somewhat controversial, but are typical signs of dysregulated innate immune function in diabetes (Fig. 1) . Dysfunction of innate immune cells is believed to be involved in various diabetes related complications. Future study should focus on the underlying mechanism of diabetes mediated neutrophil and macrophage dysfunction.
Dysregulated complement activation in diabetes
The complement system is an important part of the innate immune system, consisting of over 30 proteins that are produced predominately by the liver. In the absence of infection, complement proteins circulate in an inactive form. Upon stimulation, they are cleaved by relevant proteases resulting in amplifying cascades Fig. 1 . Systemic innate immune dysregulation in diabetes. The innate immune system constitutes innate immune cells and the complement system. During diabetes, hyperglycemia reduces the phagocytosis, bactericidal activity, and chemotaxis of neutrophils and monocytes, leading to increased risk of infection and reduced wound healing. On the other hand, the metabolic intermediates stimulate neutrophil and monocyte activation resulting in inflammatory cytokine production and adhesion molecule expression. Activated neutrophils and macrophages contribute to tissue damage in various diabetes related complications. During diabetes the levels of complement activators, including C3, MBL and autoantibodies are increased, whereas the activity the regulators such as CD59 are reduced by non-enzymatic glycation. Together this leads to increased complement activation, which may also contribute to tissue damage in diabetic complications.
involving further cleavage, and ultimately the formation of the membrane attack complex (MAC), a potent molecule that can kill cells (Zipfel & Skerka, 2009 ). The complement system can be activated through the classical pathway (CP, mediated by antibodyantigen complex), the alternative pathway (AP, spontaneous tickover) and the lectin pathway (LP, mediated by mannose-binding lectin (MBL) or ficolin binding to certain sugars) (Zipfel & Skerka, 2009 ). In addition to MAC, complement activation also generates various complement fragments, including C3a, C5a, and C4a, that are actively involved in various immune responses (Zipfel & Skerka, 2009) .
Diabetes may affect the production and function of complement proteins and regulators. CD59 is a membrane glycoprotein that inhibits C9 polymerization and thus preventing MAC formation. During debates, CD59 can be inactivated by non-enzymatic glycation (Qin et al., 2004) . The blood level of glycated CD59 (GCD59) in diabetes is reported to be positively associated with glucose levels, and GCD59 has been proposed as a biomarker of diabetes (Ghosh et al., 2013; Ghosh et al., 2014) . In addition, the auto-antibodies against glycated and glycol-oxidized proteins (Lopes-Virella et al., 1999) may initiate the CP complement activation in diabetes. Whereas AGEs can serve as neo-epitopes for MBL binding (Hansen et al., 2010) .
Increased plasma levels of C3 have been observed in both T1D and T2D patients and is associated with vascular thrombosis (Hess et al., 2012; Hess et al., 2014; Wei et al., 2012) . Higher levels of soluble MAC in the blood increase the risk of cardiovascular events in T2D patients (Mellbin, Bjerre, Thiel, & Hansen, 2012) . The serum levels of the MBL are increased in T1D (Hansen et al., 2003) and T2D (Guan, Tong, & Xu, 2015) and is positively associated with diabetic nephropathy (Guan et al., 2015; Kaunisto et al., 2009 ) and retinopathy (Geng, Ding, Qiu, & Lu, 2015; Huang et al., 2015) . Higher levels of MBL on its own or in combination with higher levels of C-reactive protein (CRP) predict the mortality in T2D (Hansen et al., 2003) . The levels of MAC deposition in the kidney are reported to be positively associated with tissue damage (Qin et al., 2004) . Taken together, diabetes appears to induce uncontrolled complement activation, which may contribute to various diabetic complications (Fig. 1 ).
Dysregulated innate immunity in diabetic retinopathy
Retinal immune privilege and immune defense
The retina is protected from systemic immune attack by a highly complex, sophisticated system and is considered an immune privilege tissue (Forrester, Xu, Lambe, & Cornall, 2008; Gregerson, 1998; Streilein, Ma, Wenkel, Ng, & Zamiri, 2002) . Firstly, the retina is segregated from the systemic immune system by a physical barrier, i.e., the blood retina barrier (BRB) that is formed by tight junctions between retinal vascular endothelial cells (inner BRB, iBRB) and RPE cells (outer BRB, oBRB), therefore circulating cells and molecules are not able to move freely into the retinal parenchyma. The BRB also segregates retinal antigens within the intraocular compartment therefore avoiding T cell activation. This phenomenon is known as immunological ignorance (Avichezer et al., 2003; Forrester, Xu, Kuffova, Dick, & McMenamin, 2010; Forrester et al., 2008) . Secondly, there is no lymphatic system in the retina. Therefore, when the retina suffers from endogenous insults, the alarmins (DAMPs) are unlikely to be detected by circulating or choroidal/extraocular immune cells. Thirdly, the retina has a sophisticated immune regulatory system that is orchestrated by retinal neurons and RPE cells (Streilein, 1999; Streilein et al., 2002; Wenkel & Streilein, 2000) . These retinal cells express various immune modulators that can suppress myeloid cell (microglia/macrophage) activation via the CD200-CD200R (Dick et al., 2003) or CX3CL1-CX3CR1 (Combadiere et al., 2007) pathway, or reduce T cell activation or induce T regulatory cell (Treg) formation (through thrombospondin-1, TGF-b, CTLA4, CTLA2 (Horie, Sugita, Futagami, Yamada, & Mochizuki, 2010; Kawazoe et al., 2012; Mochizuki, Sugita, & Kamoi, 2013; Sugita et al., 2008; Sugita et al., 2009; Zamiri, Masli, Kitaichi, Taylor, & Streilein, 2005) . RPE cells can induce apoptosis in infiltrating immune cells through Fas ligand (FasL) and Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) pathways (Ferguson & Griffith, 1997; Kazama et al., 2008; Ferguson & Griffith, 2007) , or suppress complement activation via CD55, CD46, and CD59 (Sohn, Kaplan, Suk, Bora, & Bora, 2000; Sohn et al., 2007) . In addition, ocular fluids also contain a number of immunoinhibitory molecules such as TGF-b2, neuropeptides (e.g., a-melanocyte-stimulating hormone), and vasoactive intestinal peptide (Taylor, 1996; Taylor & Lee, 2010) . The mechanisms of retinal immune privilege have been reviewed extensively elsewhere (Refs Avichezer et al., 2003; Dick et al., 2003; Forrester et al., 2008; Forrester et al., 2010; Gregerson, 1998; Streilein, 1999; Streilein et al., 2002; Wenkel & Streilein, 2000) .
In addition to the immune regulatory system, the retina also has an immune defense system that is executed by microglia, perivascular macrophages, and the complement system. The topic of retinal defense system has been reviewed previously (Chen & Xu, 2015; Gregerson, 1998; Xu, Chen, & Forrester, 2009 ). Microglia are originated from Yok-sac macrophages (Prinz & Mildner, 2011) . In the adult retina, they are located in the inner layers of the neuronal retina: the ganglion cell layer, inner plexiform layer, and outer plexiform layer (Chen & Xu, 2015) . Although both perivascular macrophages and microglia express CD11b and F4/80, the former express high levels of CD14 (LPS receptor) and CD45, whereas microglial cells are negative for CD14 and express low levels of CD45 (Dick, Ford, Forrester, & Sedgwick, 1995; Fischer & Reichmann, 2001; Tavazzi, Morrison, Sullivan, Morgello, & Fischer, 2014) . A number of complement proteins (e.g., C1q, C3, factor B etc.) and regulators (factor H, CD46, CD59 etc.) can be produced locally by retinal cells (Xu & Chen, 2016) . The retinal defense system can detect and respond to PAMPS or DAMPs and plays an important role in retinal homeostasis, and such activation is tightly controlled.
Compromised immune privilege in diabetic retinopathy
DR is the progressive degeneration of retinal vasculature and neurons leading to loss of visual function. Clinical symptoms of DR are often related to the loss of retinal immune privilege, including the breakdown of BRB and changes in retinal immune suppressive properties. For example, diabetic macular oedema (DMO) is the direct consequence of the breakdown of BRB. Multiple mechanisms may be involved in the breakdown of BRB in DR. Metabolic disorder in endothelial cells may lead to vascular dysfunction and disruption of tight junctions between endothelial cells and retinal pigment epithelial (RPE) cells. Circulating immune cells, including neutrophils and monocytes are activated leading to increased leukocyte-endothelial interaction (leukostasis). We have shown that activation of both endothelial cells and leukocytes are essential for a prolonged (>20 s) cell-cell interaction (Serra et al., 2012) . The leukostasis may stimulate inflammatory cytokine (e.g., TNFa) production and induce cell death (Chibber, Ben-Mahmud, Chibber, & Kohner, 2007; Kern, 2007) leading to disruption of the BRB. In addition, serum proteins, including immunoglobulins (Ig) and complement proteins may leak into the parenchyma of the retina and further damage blood vessels. Autoantibodies against retinal pericytes may induce vas-cular damage through CP-mediated complement activation .
The immune suppressive microenvironment of the retina may also be compromised in DR. Neuronal degeneration, including ganglion cell death, amacrine and photoreceptor damage, and loss of synaptic connectivities (Hombrebueno, Chen, Penalva, & Xu, 2014) were observed in DR. Retinal neurons critically control microglial activation through the CD200-CD200R and CX3CL1-CX3CR1 pathways Forrester et al., 2008) . Neuronal degeneration may lead to dysfunction of these pathways resulting in uncontrolled microglial activation. High levels of the soluble form of CD200 have been detected in the vitreous of DR patients . A recent study has shown that CX3CR1 deficiency accelerates the development of retinopathy (Beli et al., 2016) . Clinical studies have detected higher levels of inflammatory cytokines in the vitreous from PDR patients (Koskela, Kuusisto, Nissinen, Savolainen, & Liinamaa, 2013; Muramatsu et al., 2013) . This suggests that the retina is subjected to a pro-inflammatory microenvironment, although this could be due to the overwhelming pro-inflammatory stimuli or loss of anti-inflammatory properties or both. The impact of diabetes on retinal immune suppressive mechanisms and its contribution to DR pathogenesis remains to be elucidated.
Unlike uveoretinitis whereby the retina is frequently attacked by the uncontrolled immune response (infectious or autoimmune) due to the loss of immune privilege, DR retina does not suffer from an increased risk of infection or overt inflammatory attack by the peripheral immune system. This suggests that the DR retina still has significant levels of ''privilege". The presence of microaneurysms and capillary non-perfusion in DR patients are indicatives of vascular endothelial damage. However, patients can have a dry macula most of the time and DMO only occurs occasionally during their lifetime. This suggests that the tight junctions between endothelial cells or RPE cells remain functional in DR (although sub-threshold BRB leakage may occur from time to time); and significant breakdown of the barrier only happens when the intraretinal levels of VEGF or other cytokines (e.g., inflammatory cytokines) reach above the threshold level. Various autoantibodies, including anti-aldolase Ab (Ahn et al., 2006) and antipericyte Ab (Attawia & Nayak, 1999; Li et al., 2012) have been detected in the plasma of DR patients. DR tissue may contain aldolase or pericyte antigens, and these autoantibodies may be involved in DR pathogenesis . However, the absence of overt inflammation in DR suggests the lack of sufficient amounts of retinal-specific autoantibodies or T cells (if they exist), and DR may not be viewed as an autoimmune disorder.
Retinal innate immune activation in diabetic retinopathy
As an immune privileged tissue, retinal immune response to diabetes-mediated insults during the development of DR can be classified into two stages, ''privileged stage" when the BRB remain functional and immune privilege is maintained, and ''compromised stage" when the BRB is broken down and the immune privilege is compromised (Fig. 2) . During the ''privileged stage", the inflammatory stimulators and responders are both retinal origin, whereas in ''compromised stage", the stimulators and responders of inflammation are the mixed components from retinal tissue and circulation. The two stages are, however, inter-changeable during the course of DR. For example, when patients develop DMO, the retinal immune response is in ''compromised stage", and when DMO is cured and patients regain a ''dry" macula, the immune response returns to ''privileged stage" although the stimulators and responders may no longer be solely retinal origin. Blood-derived immune stimulators and responders may remain in the neuronal retina after the BRB is repaired and DMO is cured, although their activation is well-controlled in the retinal microenvironment.
Microglial activation in diabetic retinopathy
As discussed earlier, microglia and the complement system safeguard the retina from exogenous and endogenous insults. Under normal physiological conditions, microglia sense surrounding danger signals through various PPRs (Jack et al., 2005; Lehnardt et al., 2006) . Upon engaging with danger signals, they may convert from a resting surveillance state to an active form specialized to operate within the diseased environment (Chen & Xu, 2015) . Depending on the nature and magnitude of the danger stimuli, microglia may undergo different levels of activation, i.e., a lowlevel of noxious danger molecules may induce mild microglial activation, whereas acute damage or infection may induce full activation (highly motile and amoeboid shape) (Chen & Xu, 2015; Langmann, 2007) .
During the early stages of DR (when BRB is largely intact and immune privilege is maintained), metabolic disorder results in the accumulation of oxidized-or glycated-lipoproteins such as AGEs, advanced lipoxidation end-products (ALEs), and oxidized LDL, which pose a low-level of threat to the retina (Chen, Curtis, & Stitt, 2013) , and the threat is detected by retinal microglia through cell surface PRRs. In addition, hyperglycemia is a noxious microenvironment and can induce microglial activation through reactive oxygen species (ROS)-mediated NF-jB activation (Du, Smith, Miller, & Kern, 2002) (Fig. 2A) . In streptozotocin (STZ)-induced diabetic rats, increased microglial cell numbers was observed shortly after the onset of diabetes (Zeng, Green, & Tso, 2008) , peaked at 4-6 months in the inner plexiform layer coinciding with the decrease in the number of neuronal cells. By 14-16 months, activated microglia were observed in the outer nuclear layer (Zeng et al., 2008) . It should be noted that mild BRB breakdown measured by vascular hyper-permeability occurs within a couple of weeks in STZ-induced rat/mouse models, and microglial activation in the rodent models of DR may result from mild BRB breakdown. Nevertheless, microglial activation is mild at the early stages of DR, and the low-levels of resident innate immune cell activation (para-inflammation) under chronic stress conditions is regarded as a protective response to maintain homeostasis (Chen & Xu, 2015; Medzhitov, 2008; Xu et al., 2009 ). Active microglia may play an important role in removing metabolic insults at the ''privilege stage" of DR, they may also release low-levels of proinflammatory mediators that may potentially damage retinal cells, including vascular endothelial cells. The low-levels of inflammatory insults may be tolerated for years and decades and patients may maintain a good visual function. However, sustained diabetic insults may override the protective capacity of para-inflammatory response, and detrimental chronic inflammation may occur, leading to significant BRB damage (see below). The dysregulated para-inflammation may contribute to retinal pathologies (Chen & Xu, 2015) .
When the BRB is damaged in DR, serum proteins such as complements, cytokines and chemokines may leak into the retinal parenchyma causing additional insults. Retinal immune response moves to the ''compromised stage", whereby microglia are activated by both retinal origin and blood-derived DAMPs. In addition, circulating immune cells such as neutrophils and macrophages may infiltrate the retina. Infiltrating immune cells together with the uncontrolled active microglia may contribute to retinal pathologies in DR (Fig. 2B) . Due to the lack of appropriate animal models, our understanding on how microglia respond to serum proteins in the context of DR is limited. It will be important to know which receptors are involved in detecting serum proteins and which inflammatory cytokines are released by active microglia in DR.
In addition to the aforementioned ''danger" molecules, the inhibitory molecules such as CD200 and CX3CL1 in retinal neurons may be reduced (as a result of DR-related neuronal degeneration), which may also contribute to microglial activation ( Fig. 2A) . Diabetes-induced retinal microglial activation is enhanced in Cx3cr1 deficient mice (Kezic, Chen, Rakoczy, & McMenamin, 2013) . Further studies are necessary to understand the role of these inhibitory pathways in human DR development.
Complement activation in diabetic retinopathy
As an immune privileged tissue, circulating complement proteins are not able to move freely to the neuronal retina when the BRB is intact. However, retinal cells, including neurons (Anderson et al., 2010) , microglia, and RPE cells can produce various complement proteins (e.g., C1qa/b, C1s, Cr1, C2, C4, Cfb, Cfd, C5, and C7) and complement regulators (e.g., Serping-1, MCP (CD46), DAF (CD55), CFH, CFI, and CD59) (Chen, Forrester, & Xu, 2007; Chen, Muckersie, Robertson, Forrester, & Xu, 2008; Luo, Chen, & Xu, 2011; Xu & Chen, 2016) . A complement regulatory system exists in the retina and it plays an important role in retinal health and disease.
Dysregulated complement activation is known to be involved in DR (Yang et al., 2006) . Genetic studies have shown that the polymorphisms of the complement C5 gene are associated with PDR in T2D patients Yang et al., 2016) . Higher levels of systemic complement activation are known to be positively correlated with DR progression (Geng et al., 2015) . The choriocapillaris of DR eyes contain significant levels of C3d and MAC (Gerl et al., 2002) . MAC deposition was also detectable in the retinal vessels of patients with >9-year T2D (Zhang, Gerhardinger, & Lorenzi, 2002) . Increased C5a (Muramatsu et al., 2013) , C3 and CFI have been detected in the vitreous of PDR eyes (Gao, Chen, Timothy, Aiello, & Feener, 2008; Wang, Feng, Hu, Xie, & Wang, 2013) . Taken together, the results suggest higher levels of local complement activation in DR.
Multiple mechanisms may be involved in DR-related complement activation. During the ''privileged stage", the expression and function of complement proteins and regulators may be affected by retinal endogenous metabolic intermediates. Reduced expression or impaired function (as a result of non-enzymatic glycation) of complement regulators, including CD55 and CD59 has been observed in diabetes (Ghosh, Sahoo, Vaidya, Chorev, & Halperin, 2015; Zhang et al., 2002) . When the BRB is compromised, serum proteins including complement and immunoglobulins may leak into and accumulate in the diabetic retina and trigger complement activation. For example, retinal pericyte-reactive autoantibodies have been detected in the plasma of DR patients (Zhang et al., 2016) , and it has been suggested that antibody mediated classical pathway of complement activation may be involved in pericyte death and vascular degeneration in DR .
Complement activation may contribute to DR development at multiple levels. Complement fragments such as C3a and C5a may engage with relevant receptors on retinal cells and induce inflammatory or angiogenic growth factor production. Muller cells constitutively express C5aR and the expression can be upregulated by hyperglycemia and inflammatory stimuli such as PGE2 (Cheng et al., 2013) . The ligation of C5aR with C5a in Muller cells results in the release of IL-6 and VEGF (Cheng et al., 2013) -both are known to be critically involved in DR pathology. MAC deposition may directly damage retinal cells, such as pericytes . Preventing MAC formation and deposition in the retina through adeno-associated virus mediated delivery of CD59 attenuates DR pathologies (e.g., reduced vascular degeneration and ganglion cell death) (Adhi, Cashman, & Kumar-Singh, 2013) , which further supports the role of MAC in DR pathogenesis (Fig. 2B) .
Systemic innate immune activation in diabetic retinopathy
As discussed above, the systemic innate immune system is activated at the early stages of diabetes and the activation may be dysregulated at the complication stages (Josefsen et al., 1994) . As an immune privileged tissue the retina would not be affected by systemic innate immune activation as long as the BRB is intact. However, activation of circulating immune cells may contribute towards the failure of BRB at the early stages of DR (Chibber et al., 2007; Kern, 2007) (Fig. 1) , and may contribute even more so towards retinal neuronal and vascular damage and the growth of new vessels when the BRB is compromised during the advanced stages of DR (Fig. 2B) . A previous study has shown that neutrophils are trapped in retinal blood vessels prior to the development of DR in T1D patients (Valle et al., 2013) . Experimental studies have shown that leukocyte-endothelial interaction in diabetes induces vascular damage, which is a major contributor of retinal vasculopathy (Chibber et al., 2007) . Circulating levels of neutrophil extracellular trap (Park et al., 2016) and MBL (Geng et al., 2015) were increased and positively correlated with DR. These results suggest that dysregulated systemic innate immune activation contributes to the pathogenesis of DR. At the advanced stages of DR, when the BRB is compromised, activated neutrophils and monocytes and complement proteins may infiltrate the retina promoting inflammation and tissue damage (Rangasamy, McGuire, & Das, 2012) (Fig. 2B) . Infiltrating immune cells (e.g., macrophages, neutrophils and lymphocytes) have been detected in the inner side of the internal limiting membrane of diffuse DMO patients (Tamura, Yokoyama, Ebihara, & Murakami, 2012) and in epiretinal membranes from PDR patients (Urbancic, Stunf, Milutinovic Zivin, Petrovic, & GlobocnikPetrovic, 2014) . Vitreous samples from PDR patients contains significant amounts of macrophages (Canataroglu et al., 2005) . These results suggest that infiltrating immune cells are involved in the development of neovascular membrane in PDR.
The effect of immune suppression in diabetic retinopathy
The contribution of dysregulated innate immune activation to the pathogenesis of DR is supported by the strong therapeutic effect of immune suppression in DR. A few steroids, including triamcinolone, fluocinolone, and dexamethasone are being used to treat DMO (Bandello et al., 2012; Das, McGuire, & Rangasamy, 2015) . When the steroids are injected intravitreally to patients, DMO can be effectively controlled (i.e., reduced macular thickness, improved visual function, etc). This suggests that inflammation contributes significantly to DMO pathology. The therapeutic effects of the steroids, however, only last for 4-6 weeks and repeated intravitreal injections are needed. The use of slow-release steroids implants, including Ozurdex (biodegradable dexamethasone intravitreal implant), Retisert and Iluvien (Fluocinolone acetonide intravitreal implant) has significantly improved clinical outcomes of DMO management (Dugel, Bandello, & Loewenstein, 2015) .
The results suggest that sustained retinal chronic inflammation contributes to DR pathogenesis. Dysregulated innate immune regulation may underline diabetes-induced chronic inflammation.
Conclusion
Although metabolic insults are the primary triggers of DR, inflammation, in particular dysregulated innate immune activation contributes significantly to the pathogenesis. At the early stages of DR when the BRB is intact, the retinal innate immune system, i.e., microglia and the complement system, is activated at low levels in response to noxious insults from intraretinal metabolic intermediates (e.g., AGE, ALE, oxLDL, etc.). The physiological purpose of this low-level of innate immune activation (para-inflammation) within the immune privileged retina is to remove the danger molecules and maintain homeostasis ( Fig. 2A) . In the meantime, the circulating innate immune cells, such as neutrophils and monocytes are also activated leading to a low level of intravascular inflammation in the form of ''leukostasis" (Chibber et al., 2007; Kern, 2007) . Sustained metabolic stimuli in diabetes may lead to maladaptation of the innate immune system both systemically and locally. Metabolic disorder in immune cells may also contribute to maladaptation. Maladapted innate immune activation (chronic inflammation) ultimately damages the BRB leading to the loss of immune privilege. During the late stages of DR when immune privilege is compromised, circulating immune cells and serum proteins infiltrate the retina, which further damages blood vessels and neurons (Fig. 2B) . Further understanding how the innate immune system is maladapted/dysregulated and which key inflammatory mediators are released at different stages of DR will uncover novel targets for immune therapy.
